Detection of germline predisposition in acute myeloid leukemia

This study examines the prevalence and clinical implications of germline mutations in acute myeloid leukemia (AML) by utilizing next-generation sequencing (NGS) on paired diagnostic and complete remission (CR) samples from 343 patients. Germline mutations were identified in 5.5% of the cohort, with DDX41 being the most commonly mutated gene. These mutations were more frequently observed in patients with intermediate or adverse cytogenetic profiles and were associated with distinct clinical characteristics, including hypoplastic bone marrow and lower blast counts. Although germline mutations were associated with a trend towards poorer overall survival, this finding did not reach statistical significance in multivariate analysis. The study underscores the importance of NGS in identifying germline mutations, which can influence risk stratification and therapeutic decisions, particularly in the context of allogeneic hematopoietic cell transplantation (HCT). These results suggest that patients with germline mutations might benefit from tailored treatment strategies, including consideration for early transplantation. The findings also emphasize the need for further research to expand genetic panels and better understand the functional impact of these mutations, ultimately guiding more personalized and effective treatment approaches in AML.